BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $149,991.68 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of BridgeBio Pharma stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $36.16, for a total transaction of $149,991.68. Following the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,705,098.24. The trade was a 3.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

BridgeBio Pharma Stock Performance

NASDAQ BBIO opened at $36.85 on Friday. The business’s 50 day moving average price is $31.90 and its 200-day moving average price is $27.93. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $39.47. The company has a market cap of $6.96 billion, a P/E ratio of -15.29 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million. As a group, equities analysts predict that BridgeBio Pharma, Inc. will post -2.56 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently added to or reduced their stakes in BBIO. Mackenzie Financial Corp lifted its stake in BridgeBio Pharma by 6.6% in the fourth quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after purchasing an additional 592 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of BridgeBio Pharma in the fourth quarter worth approximately $109,000. Frazier Life Sciences Management L.P. lifted its stake in shares of BridgeBio Pharma by 1.1% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock worth $104,285,000 after acquiring an additional 40,000 shares during the last quarter. Woodline Partners LP boosted its holdings in BridgeBio Pharma by 132.9% during the 4th quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock valued at $60,684,000 after acquiring an additional 1,261,772 shares during the period. Finally, Zimmer Partners LP bought a new position in BridgeBio Pharma in the 4th quarter valued at $4,950,000. 99.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $49.00 target price on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Evercore ISI raised their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Monday, December 23rd. Bank of America boosted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Cantor Fitzgerald restated an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a report on Friday. Finally, Scotiabank upped their price objective on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has an average rating of “Moderate Buy” and a consensus target price of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.